表紙
市場調査レポート

世界のリソソーム蓄積症市場

Global Lysosomal Storage Diseases Market 2014-2018

発行 TechNavio (Infiniti Research Ltd.) 商品コード 310019
出版日 ページ情報 英文 64 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
世界のリソソーム蓄積症市場 Global Lysosomal Storage Diseases Market 2014-2018
出版日: 2014年07月30日 ページ情報: 英文 64 Pages
概要

世界のリソソーム蓄積症市場は、2013年から2018年にかけて、10.01%のCAGR(複合年間成長率)で拡大すると予測されています。

当レポートでは、世界のリソソーム蓄積症市場の現状と今後の見通し、薬剤クラス・地域別の動向、市場の発展因子と課題、主なベンダーのプロファイルなどを提供しています。

第1章 エグゼクティブサマリー

第2章 略語リスト

第3章 調査範囲

  • 市場概要
  • 主な製品

第4章 市場調査手法

  • 市場調査プロセス
  • 調査手法

第5章 イントロダクション

第6章 疾病の概要

第7章 市場情勢

  • 市場概要
  • 市場規模・予測
  • リソソーム蓄積症治療の最初の認可薬
  • ファイブフォース分析

第8章  市場区分:薬剤クラス別

  • ERT
  • SRT
  • Cystine-Depletors

第9章 地域区分

第10章 購入基準

第11章 市場成長因子

第12章 成長因子とその影響

第13章 市場の課題

第14章 成長因子と課題の影響

第15章 市場動向

第16章 動向とその影響

第17章 ベンダー情勢

  • 競合シナリオ
    • 主なニュース
    • M&A
  • 市場シェア分析
    • Genzyme
    • Shire
    • BioMarin
    • Actelion

第18章 その他

  • その他の有望ベンダー

第19章 主要ベンダーの分析

  • Actelion
    • 事業概要
    • 主要情報
    • SWOT分析
  • BioMarin
  • Genzyme
  • Shire

第20章 関連レポート

図表リスト

目次
Product Code: IRTNTR3860

About Lysosomal Storage Diseases

The term lysosomal storage diseases refers to a group of rare inherited disorders caused by the deficiency of lysosomal enzymes, activator proteins, proteins required for normal post-translational modification of lysosomal enzymes or proteins required for intracellular transport between lysosome and other cellular compartments. These deficiencies result in deficient enzymatic activity which, in turn, leads to accumulation of partially digested or undigested macromolecules inside the cell. The clinical manifestations of lysosomal storage diseases depend on the type of substrate stored, cell types affected by this storage, and resulting organ involvement. Due to the high variability of these components, the clinical manifestations of even a single disease vary from person to person. These symptoms also vary between members of the same family with identical mutations. The age of onset also varies for lysosomal storage diseases depending on the rate of substrate accumulation. Lysosomal storage diseases are classified on the basis of the substrate being accumulated or on the type of molecular defect associated with the disease. Neuronal ceroid-lipofuscinoses vary from classical lysosomal storage diseases where the component that gets accumulated is mitochondrial ATP synthase subunit C or sphingolipid activator proteins A and D.

TechNavio's analysts forecast the Global Lysosomal Storage Diseases market will grow at a CAGR of 10.01 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Lysosomal Storage Diseases market for the period 2014-2018. To calculate the market size, the report considers revenue from the sales of various drugs available in the market for the management of different types of lysosomal storage diseases, which include:

  • Gaucher disease
  • Fabry disease
  • Mucopolysaccharidosis
  • Pompe disease
  • Cystinosis
  • NPC

TechNavio's report, the Global Lysosomal Storage Diseases Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Lysosomal Storage Diseases market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Actelion Pharmaceuticals Ltd.
  • BioMarin Pharmaceutical Inc.
  • Genzyme Corp.
  • Shire plc

Other Prominent Vendors

  • Mylan
  • Pfizer
  • Protalix
  • Raptor
  • Recordati
  • Sigma-Tau

Key Market Driver

  • Special Provisions for Orphan Drugs

For a full, detailed list, view our report.

Key Market Challenge

  • Increase in Generic Erosion

For a full, detailed list, view our report.

Key Market Trend

  • Fierce Market Competition
  • Increasing Use of Statins.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • Product Portfolio

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Disease Overview

07. Market Landscape

  • 07.1. Market Overview
  • 07.2. Market Size and Forecast
  • 07.3. First Approved Drugs for Treatment of Lysosomal Storage Diseases
  • 07.4. Five Forces Analysis

08. Market Segmentation by Drug Class

  • 08.1.1. ERTs
  • 08.1.2. SRT
  • 08.1.3. Cystine-Depletors

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

  • 17.1. Competitive Scenario
    • 17.1.1. Key News
    • 17.1.2. Mergers and Acquisitions
  • 17.2. Market Share Analysis 2013
    • 17.2.1. Genzyme
    • 17.2.2. Shire
    • 17.2.3. BioMarin
    • 17.2.4. Actelion

18. Others

  • 18.1. Other Prominent Vendors

19. Key Vendor Analysis

  • 19.1. Actelion
    • 19.1.1. Business Overview
    • 19.1.2. Key Information
    • 19.1.3. SWOT Analysis
  • 19.2. BioMarin
    • 19.2.1. Business Overview
    • 19.2.2. Key Information
    • 19.2.3. SWOT Analysis
  • 19.3. Genzyme
    • 19.3.1. Business Overview
    • 19.3.2. Key Information
    • 19.3.3. SWOT Analysis
  • 19.5. Shire
    • 19.5.1. Business Overview
    • 19.5.2. Key Information
    • 19.5.3. SWOT Analysis

20. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Classification of Lysosomal Storage Diseases
  • Exhibit 3: Global Lysosomal Storage Diseases Market 2013-2018 (US$ billion)
  • Exhibit 4: Global Lysosomal Storage Diseases Market Segmentation by Drug Class
  • Exhibit 5: Global Lysosomal Storage Diseases Market Segmentation by Drug Class 2013
  • Exhibit 6: Global Lysosomal Storage Diseases Market by Geographical Segmentation 2013
  • Exhibit 7: Market Revenue for Major Drugs 2013
  • Exhibit 8: Percentage Revenue Share of LSD Drugs of Genzyme 2013
  • Exhibit 9: Geography-wise Revenue of Genzyme Corp.'s LSD Products in 2013 (US$ million)
  • Exhibit 10: Geography-wise Revenue of Genzyme Corp's LSD Products in 2013
  • Exhibit 11: Geography-wise Revenue of Naglazyme in 2013 (US$ million)
Back to Top